BRITANNIA LIFE SCIENCES (L020) - Total Assets
Based on the latest financial reports, BRITANNIA LIFE SCIENCES (L020) holds total assets worth €22.06 Million EUR (≈ $25.79 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See BRITANNIA LIFE SCIENCES shareholders equity for net asset value and shareholders' equity analysis.
BRITANNIA LIFE SCIENCES - Total Assets Trend (2022–2025)
This chart illustrates how BRITANNIA LIFE SCIENCES's total assets have evolved over time, based on quarterly financial data.
BRITANNIA LIFE SCIENCES - Asset Composition Analysis
Current Asset Composition (March 2025)
BRITANNIA LIFE SCIENCES's total assets of €22.06 Million consist of 85.5% current assets and 14.5% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 67.6% |
| Accounts Receivable | €228.11K | 2.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2022–2025)
This chart illustrates how BRITANNIA LIFE SCIENCES's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of BRITANNIA LIFE SCIENCES.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BRITANNIA LIFE SCIENCES's current assets represent 85.5% of total assets in 2025, an increase from 16.5% in 2022.
- Cash Position: Cash and equivalents constituted 67.6% of total assets in 2025, up from 7.7% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 80.0% in 2022.
- Asset Diversification: The largest asset category is accounts receivable at 2.0% of total assets.
BRITANNIA LIFE SCIENCES Competitors by Total Assets
Key competitors of BRITANNIA LIFE SCIENCES based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT
|
USA | $285.41 Million |
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SHG:603392
|
China | CN¥13.76 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653
|
China | CN¥7.21 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥772.57 Million |
BRITANNIA LIFE SCIENCES - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.55 | 0.20 | 0.25 |
| Quick Ratio | 3.55 | 0.18 | 0.23 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €12.19 Million | €-9.31 Million | €-8.59 Million |
BRITANNIA LIFE SCIENCES - Advanced Valuation Insights
This section examines the relationship between BRITANNIA LIFE SCIENCES's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.58 |
| Latest Market Cap to Assets Ratio | 0.68 |
| Asset Growth Rate (YoY) | -47.8% |
| Total Assets | €11.61 Million |
| Market Capitalization | $7.87 Million USD |
Valuation Analysis
Below Book Valuation: The market values BRITANNIA LIFE SCIENCES's assets below their book value (0.68x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: BRITANNIA LIFE SCIENCES's assets decreased by 47.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for BRITANNIA LIFE SCIENCES (2022–2025)
The table below shows the annual total assets of BRITANNIA LIFE SCIENCES from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | €11.61 Million ≈ $13.57 Million |
-47.85% |
| 2024-03-31 | €22.26 Million ≈ $26.03 Million |
-5.46% |
| 2023-03-31 | €23.55 Million ≈ $27.53 Million |
+11.66% |
| 2022-03-31 | €21.09 Million ≈ $24.66 Million |
-- |
About BRITANNIA LIFE SCIENCES
Britannia Life Sciences Inc. engages in the product testing, safety assessment, and manufacturing services in the United Kingdom and internationally. It serves cosmetics, consumer packaged and household goods, and nutraceutical industries. The company is headquartered in Toronto, Canada.